Clinical profile of COVID‐positive children with cancer and their follow‐up: A tertiary care center's experience from a developing country

• Published in: Pediatric Blood & Cancer Vol. 69; no. 7; pp. e29559 - n/a
• Main Authors: Sneha, Latha M., Niranjani, M. U., Dhaarani, J., Balaji, T. K., Arul, Janani, Scott, Julius Xavier
• Format: Journal Article Web Resource
• Language: English
• Published: United States John Wiley & Sons, Inc 01.07.2022; Wiley Subscription Services, Inc
• Subjects: Hematology; Oncology; Pediatrics
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.29559

With various studies quoting different rates of severity and mortality in these children ranging between 4.9% and 50%, we conducted a prospective study of incidence and outcomes of COVID positivity among children with malignancies treated between March 2020 and September 2021.2, 3 All children <18 years of age with malignancies admitted between March 2020 to September 2021 were included in this prospective study. Remission Cough, cold Observation Alive 4 M LCH Remission Asymptomatic Home quarantine Alive 0.7 M Wilms tumor Remission Asymptomatic Home quarantine Alive 0.9 M Retinoblastoma Remission Asymptomatic Home quarantine Alive Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; GCT, germ cell tumor; LCH, Langerhans cell histiocytosis; NHL, non-Hodgkin lymphoma; RMS, rhabdomyosarcoma. a First case to be diagnosed, hence observed in ward for 1 week. b Newly diagnosed leukemias, hence observed in ward for 1 week. c Child with intracranial germ cell tumor with hyponatremia, hence observed in ward for 72 hours. Clinical characteristics and evolution of pediatric patients with acute leukemia and SARS-COV2 virus infection in a third level hospital in Mexico.